Arrowhead Pharmaceuticals, Inc. (ARWR) financial analysis and rating

Comparison analysis based on SEC data

Company Name Arrowhead Pharmaceuticals, Inc.
Industry (SIC) 2834 - Pharmaceutical Preparations
Latest report 12/31/2021 (filed 2/02/2022)
Revenue $144 million (ranked #203 out of 633 companies in the industry)
Assets $639 million (ranked #188)

Financial position and performance

Compared with industry ratios Change during the year

about the same

deteriorated considerably
Compared with all industry ratios

about the same

Compare with a competitor

Financial ratios benchmarking (TTM)

Finanancial ratio Compared
with industry ratios
(28 - Chemicals And Allied Products)
with all industry ratios
Solvency Ratios
Debt ratio 
Debt-to-equity ratio 
Liquidity Ratios
Current Ratio 
Quick Ratio 
Cash Ratio 
Profitability Ratios
Profit margin 
ROE (Return on equity), after tax 
ROA (Return on assets) 
Activity Ratios
Asset turnover (days) 
Receivables turnover (days) 
Resulting score 0,0 +0,1

Additional ratios (not used to calculate the resulting score)

Finanancial ratio Compared
with industry ratios
(28 - Chemicals And Allied Products)
with all industry ratios
Price Ratios
Earnings per Share (basic) $-1.76
Earnings per Share (diluted) $-1.76

Auditor's conclusion

We have conducted a comparative analysis of the balance sheet and the income statement of Arrowhead Pharmaceuticals, Inc. (hereafter – the "Company") for the year 2021 submitted to the U.S. Securities and Exchange Commission (SEC). The primary business activity of the company is Pharmaceutical Preparations (SIC code 2834). During the analysis we have compared the key financial ratios of the company with the average (median) values of those ratios calculated for the specific industry sector and for all industries. The averages are calculated using the data from financial statements for the year 2021 submitted to the SEC through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). By comparing each of the eleven key metrics with the median value, we have made a generalized conclusion about the quality of the financial condition of the company. Calculations and summary conclusions are made in a computerized way using software and methods developed by Consulting financial and analytical company Ankon.

As a result of the analysis of the key financial ratios of the company, we have established the following. The financial condition of Arrowhead Pharmaceuticals, Inc. in 2021 is about the same as the financial condition typical of the companies engaged in the activity "Pharmaceutical Preparations"

Comparison of the Company’s financial ratios with average ratios for all business activities leads to the same conclusion. The financial position of Arrowhead Pharmaceuticals, Inc. is about the same as the average financial condition of the listed companies that submit financial statements to the U.S. Securities and Exchange Commission.

Financial position and performance history

Additional data about Arrowhead Pharmaceuticals, Inc.

Closest competitors

Company USD ($), in Millions
Revenue Assets
Clovis Oncology, Inc. 149 473
Seres Therapeutics, Inc. 145 355
Zai Lab Limited 144 1,610
Catalyst Pharmaceuticals, Inc. 141 238

See also all industry leaders

Financial data source and analysis principles

The above is a comparative analysis of the financial position and performance of the company. The comparison is based on official financial statements filed with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR) (about 10,000 largest publicly traded companies). The comparison is performed using the eleven key financial ratios (see table above). Company's financial ratios are compared with the median values of ratios of all companies and of companies within the same industry, and also with the quartiles of those ratios. Each ratio value is given a score ranging from -2 and +2 depending on its position relative to the quartiles (-2 – below the first quartile; -1 – between the first and the second quartile; +1 – between the second and the third quartile; +2 – above the third quartile; 0 – the ratio value deviates from the median by no more than 5% of the difference between the median and the quartile closest to the ratio value). To draw a conclusion from the analysis the individual scores are weighted equally to get an overall score ranging from -2 and +2.

much better (+1 - +2incl)
better (from 0.11 to +1incl)
about the same (from -0.11incl to +0.11incl)
worse (from -1incl to -0.11)
much worse (from -2incl to -1)
"Change during the year" calculation

Change during the year is calculated by comparing the resulting score of financial position within the industry with the last year's (quarter's) score. The result of the comparison may be as follows:

improved considerably (positive change of more than 1 point)
improved (positive change of less than 1 point)
unchanged (little or no change in score, no more than 0.11 points)
deteriorated (the score has decreased by less than 1 point during the year)
deteriorated considerably (the score has decreased by more than 1 point during the year)

Please note: The presented analysis does not indicate a poor or good financial position of the company, but gives its description relative to other U.S. businesses. For a detailed financial analysis please use "ReadyRatios Financial Analysis" - load the data into the program>>

Login to ReadyRatios


Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: